Serum osteopontin levels as a predictor of portal inflammation in patients with nonalcoholic fatty liver disease

Digestive and Liver Disease

Volumn 45, Issue 1, 2013, Pages 58-62

  Yilmaz, Yusuf ^a   Ozturk, Oguzhan ^b   Alahdab, Yesim Ozen ^a   Senates, Ebubekir ^c   Colak, Yasar ^b   Doganay, Hamdi Levent ^b   Coskunpinar, Ender ^d   Oltulu, Yasemin Musteri ^d   Eren, Fatih ^a   Atug, Ozlen ^a   Tuncer, Ilyas ^b   Imeryuz, Nese ^a  

^a MARMARA UNIVERSITY   (Turkey)

^b ISTANBUL MEDENIYET UNIVERSITY   (Turkey)

^c DICLE UNIVERSITY   (Turkey)

^d ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Biomarker; Inflammation; Nonalcoholic fatty liver disease; Osteopontin; Portal inflammation

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; OSTEOPONTIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADULT; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FATTY LIVER; FEMALE; HUMANS; INFLAMMATION; LIVER; MALE; MIDDLE AGED; OSTEOPONTIN; REGRESSION ANALYSIS;

EID: 84871607483     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2012.08.017     Document Type: Article

References (31)

1. Smith B.W., Adams L.A. Non-alcoholic fatty liver disease. Critical Reviews in Clinical Laboratory Sciences 2011, 48:97-113.
2. Moore J.B. Non-alcoholic fatty liver disease: the hepatic consequence of obesity and the metabolic syndrome. Proceedings of the Nutrition Society 2010, 69:211-220.
3. Vernon G., Baranova A., Younossi Z.M. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Alimentary Pharmacology and Therapeutics 2011, 34:274-285.
4. Dowman J.K., Tomlinson J.W., Newsome P.N. Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Alimentary Pharmacology and Therapeutics 2011, 33:525-540.
5. Vanni E., Bugianesi E., Kotronen A., et al. From the metabolic syndrome to NAFLD or vice versa?. Digestive and Liver Disease 2010, 42:320-330.
6. Almeda-Valdés P., Cuevas-Ramos D., Aguilar-Salinas C.A. Metabolic syndrome and non-alcoholic fatty liver disease. Annals of Hepatology 2009, 8(Suppl. 1):S18-S24.
7. Lund S.A., Giachelli C.M., Scatena M. The role of osteopontin in inflammatory processes. Journal of Cell Communication and Signaling 2009, 3:311-322.
8. Morimoto J., Kon S., Matsui Y., et al. Osteopontin; as a target molecule for the treatment of inflammatory diseases. Current Drug Targets 2010, 11:494-505.
9. Shang S., Plymoth A., Ge S., et al. Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology 2012, 55:483-490.
10. Zhang C.H., Xu G.L., Jia W.D., et al. Prognostic significance of osteopontin in hepatocellular carcinoma: a meta-analysis. International Journal of Cancer 2012, 130:2685-2692.
11. Giachelli C.M., Lombardi D., Johnson R.J., et al. Evidence for a role of osteopontin in macrophage infiltration in response to pathological stimuli in vivo. American Journal of Pathology 1998, 152:353-358.
12. Panzer U., Thaiss F., Zahner G., et al. Monocyte chemoattractant protein-1 and osteopontin differentially regulate monocytes recruitment in experimental glomerulonephritis. Kidney International 2001, 59:1762-1769.
13. Nystrom T., Duner P., Hultgardh-Nilsson A. A constitutive endogenous osteopontin production is important for macrophage function and differentiation. Experimental Cell Research 2007, 313:1149-1160.
14. Lima-Cabello E., García-Mediavilla M.V., Miquilena-Colina M.E., et al. Enhanced expression of pro-inflammatory mediators and liver X-receptor-regulated lipogenic genes in non-alcoholic fatty liver disease and hepatitis C. Clinical Science (London, England: 1979) 2011, 120:239-250.
15. Syn W.K., Choi S.S., Liaskou E., et al. Osteopontin is induced by hedgehog pathway activation and promotes fibrosis progression in nonalcoholic steatohepatitis. Hepatology 2011, 53:106-115.
16. Kiefer F.W., Neschen S., Pfau B., et al. Osteopontin deficiency protects against obesity-induced hepatic steatosis and attenuates glucose production in mice. Diabetologia 2011, 54:2132-2142.
17. Yilmaz Y., Eren F., Yonal O., et al. Serum progranulin as an independent marker of liver fibrosis in patients with biopsy-proven nonalcoholic fatty liver disease. Disease Markers 2011, 31:205-210.
18. Yilmaz Y., Eren F., Ayyildiz T., et al. Serum pigment epithelium-derived factor levels are increased in patients with biopsy-proven nonalcoholic fatty liver disease and independently associated with liver steatosis. Clinica Chimica Acta 2011, 412:2296-2299.
19. Yilmaz Y., Kurt R., Eren F., et al. Serum osteocalcin levels in patients with nonalcoholic fatty liver disease: association with ballooning degeneration. Scandinavian Journal of Clinical and Laboratory Investigation 2011, 71:631-636.
20. Yilmaz Y., Eren F., Kurt R., et al. Serum galectin-3 levels in patients with nonalcoholic fatty liver disease. Clinical Biochemistry 2011, 44:955-958.
21. Sanyal A.J., Brunt E.M., Kleiner D.E., et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology 2011, 54:344-353.
22. Kleiner D.E., Brunt E.M., Van Natta M., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005, 41:1313-1321.
23. ACE/ADA Task Force on Inpatient Diabetes American College of Endocrinology and American Diabetes Association Consensus statement on inpatient diabetes and glycemic control. Diabetes Care 2006, 29:1955-1962.
24. Grundy S.M., Brewer H.B., Cleeman J.I., et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004, 109:433-438.
25. Patouraux S., Bonnafous S., Voican C.S., et al. The osteopontin level in liver, adipose tissue and serum is correlated with fibrosis in patients with alcoholic liver disease. PLoS One 2012, 7:e35612.
26. Syn W.K., Agboola K.M., Swiderska M., et al. NKT-associated hedgehog and osteopontin drive fibrogenesis in non-alcoholic fatty liver disease. Gut 2012, 61:1323-1329.
27. Bertola A., Deveaux V., Bonnafous S., et al. Elevated expression of osteopontin may be related to adipose tissue macrophage accumulation and liver steatosis in morbid obesity. Diabetes 2009, 58:125-133.
28. Brunt E.M., Kleiner D.E., Wilson L.A., et al. Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network. Hepatology 2009, 49:809-820.
29. Rakha E.A., Adamson L., Bell E., et al. Portal inflammation is associated with advanced histological changes in alcoholic and non-alcoholic fatty liver disease. Journal of Clinical Pathology 2010, 63:790-795.
30. Harada K., Ozaki S., Sudo Y., et al. Osteopontin is involved in the formation of epithelioid granuloma and bile duct injury in primary biliary cirrhosis. Pathology International 2003, 53:8-17.
31. Lorena D., Darby I.A., Gadeau A.P., et al. Osteopontin expression in normal and fibrotic liver. Altered liver healing in osteopontin-deficient mice. Journal of Hepatology 2006, 44:383-390.